Long-term efficacy and safety of perampanel as a first add-on therapy in patients with focal epilepsy: Three-year extension studyopen access
- Authors
- Im, Kayeong; Lee, Sang-Ahm; Kim, Ji Hyun; Kim, Dong Wook; Lee, Sang Kun; Seo, Dae Won; Lee, Ji Woong
- Issue Date
- 12월-2021
- Publisher
- ACADEMIC PRESS INC ELSEVIER SCIENCE
- Keywords
- Epilepsy; Perampanel; Efficacy; Safety; Responder rate; Retention rate
- Citation
- EPILEPSY & BEHAVIOR, v.125
- Indexed
- SCIE
SCOPUS
- Journal Title
- EPILEPSY & BEHAVIOR
- Volume
- 125
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/144607
- DOI
- 10.1016/j.yebeh.2021.108407
- ISSN
- 1525-5050
- Abstract
- Purpose: We investigated the long-term efficacy and safety of perampanel as a first add-on therapy in patients with focal epilepsy. Methods: This retrospective study represented the 3-year extension phase of a multicenter, open-label, phase 4, prospective study of perampanel as a first add-on therapy in patients with focal epilepsy. Seizure and safety outcomes were assessed annually from the start of the extension study, and the retention rate was calculated from the start of perampanel exposure in the original study. Results: The 50% responder and seizure freedom rates were 84.8% and 58.7%, respectively, during the third year and 71.7% and 32.6%, respectively, during the entire 3-year period of the extension study. The 1-, 2-, and 3-year retention rates were 62.5%, 53.1%, and 52.1%, respectively. Efficacies were higher in patients that were aged >55 years, male, and receiving <4 mg of perampanel. Perampanel was generally well tolerated; 47.3% of patients experienced at least one adverse event during the 3 years of extension (46 adverse events (AEs) in 35 patients). The most common AEs were dizziness (33.8%), somnolence (5.4%), anger (4.1%), and irritability (4.1%). AEs were resolved with perampanel dose reduction or discontinuation in 10 (13.5%) and 12 (16.2%) patients, respectively. Conclusion: Long-term treatment with perampanel as a first add-on therapy did not raise new safety signals in patients with focal epilepsy. Especially at low perampanel doses (<4 mg/day), sustained improvement in seizure control was achieved, which could potentially avoid adverse drug reactions. (c) 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.